Limits...
The silicon supplement 'Monomethylsilanetriol' is safe and increases the body pool of silicon in healthy Pre-menopausal women.

Jugdaohsingh R, Hui M, Anderson SH, Kinrade SD, Powell JJ - Nutr Metab (Lond) (2013)

Bottom Line: There were no reported adverse effects (i.e. changes to health and well-being) or serum biochemical changes with MMST versus placebo.Our data indicate that oral MMST is safe, is absorbed and undergoes sufficient metabolism in vivo to raise fasting serum silicon levels, consistent with other well absorbed forms of dietary silicon (e.g. orthosilicic acid).It thus appears to be a suitable silicon supplement.

View Article: PubMed Central - HTML - PubMed

Affiliation: MRC Human Nutrition Research, Elsie Widdowson Laboratory, Fulbourn Road, Cambridge, CB1 9NL, UK. ravin.jugdaohsingh@mrc-hnr.cam.ac.uk.

ABSTRACT

Background: Monomethylsilanetriol (MMST) has been used for decades as an oral silicon supplement for bone and connective tissue health, although there are no formal data on its in vivo utilisation or safety following sustained dosing.

Methods: To investigate whether MMST contributes to the body pool of silicon and, secondly, to establish its safety following 4 weeks' supplementation in humans, twenty-two healthy pre-menopausal women (22-38 years) were recruited and supplemented with MMST at the maximum daily recommended dose (10.5 mg Si/day) for 4 weeks in a double-blind, randomised, placebo-controlled, cross-over design (i.e. 8 weeks in total). Fasting serum and urine samples were collected at baseline and at the end of the 4-week supplementation/placebo periods for analysis of total silicon by inductively coupled plasma optical emission spectrometry, MMST by proton nuclear magnetic resonance spectroscopy and full serum biochemistry. Participants also reported on, by questionnaire, their health, well-being and quality of life at 0, 4 and 8 weeks.

Results: Overall, 4-weeks supplementation with MMST significantly increased total fasting Si concentrations in serum and urine (P ≤ 0.003; paired t-test). MMST was semi-quantifiable in serum and quantifiable in urine, but only accounted for ca. 50% and 10%, respectively, of the increased total-Si concentration. There were no reported adverse effects (i.e. changes to health and well-being) or serum biochemical changes with MMST versus placebo.

Conclusions: Our data indicate that oral MMST is safe, is absorbed and undergoes sufficient metabolism in vivo to raise fasting serum silicon levels, consistent with other well absorbed forms of dietary silicon (e.g. orthosilicic acid). It thus appears to be a suitable silicon supplement.

No MeSH data available.


Related in: MedlinePlus

Study design. Flow diagram summarising the double-blind, randomised, placebo controlled cross-over study design.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3649945&req=5

Figure 1: Study design. Flow diagram summarising the double-blind, randomised, placebo controlled cross-over study design.

Mentions: Twenty-two healthy pre-menopausal females, aged between 22 and 38 years, with no history of serious illness and not taking any medication or silicon-containing food supplements, were recruited to the study by circular email from King’s College London (UK) (Table 1). Volunteers were excluded who were pregnant and lactating, of child-bearing age and not taking contraception, or not able to follow the study protocol. Young women were chosen because Si supplementation is likely to be most relevant in this population since epidemiological data have shown a pronounced positive association between dietary Si intakes and bone mineral density in this group [26]. Indeed, it is hypothesised that estradiol is required for Si to have any biological effect [26,27]. The women were randomly assigned to coded Placebo or MMST (silicon supplement: 10.5 mg Si/day) for 4 weeks each, in a crossover design; i.e. 11 participants took placebo for four weeks followed by MMST for four weeks and the remaining 11 participants took MMST for four weeks followed by placebo for four weeks (Figure 1). Anthropometric data (age, weight, height and BMI) were collected for each participant and there were no statistical differences in baseline parameters (see Table 1) or baseline biochemistry (Additional file 1) between the two groups.


The silicon supplement 'Monomethylsilanetriol' is safe and increases the body pool of silicon in healthy Pre-menopausal women.

Jugdaohsingh R, Hui M, Anderson SH, Kinrade SD, Powell JJ - Nutr Metab (Lond) (2013)

Study design. Flow diagram summarising the double-blind, randomised, placebo controlled cross-over study design.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3649945&req=5

Figure 1: Study design. Flow diagram summarising the double-blind, randomised, placebo controlled cross-over study design.
Mentions: Twenty-two healthy pre-menopausal females, aged between 22 and 38 years, with no history of serious illness and not taking any medication or silicon-containing food supplements, were recruited to the study by circular email from King’s College London (UK) (Table 1). Volunteers were excluded who were pregnant and lactating, of child-bearing age and not taking contraception, or not able to follow the study protocol. Young women were chosen because Si supplementation is likely to be most relevant in this population since epidemiological data have shown a pronounced positive association between dietary Si intakes and bone mineral density in this group [26]. Indeed, it is hypothesised that estradiol is required for Si to have any biological effect [26,27]. The women were randomly assigned to coded Placebo or MMST (silicon supplement: 10.5 mg Si/day) for 4 weeks each, in a crossover design; i.e. 11 participants took placebo for four weeks followed by MMST for four weeks and the remaining 11 participants took MMST for four weeks followed by placebo for four weeks (Figure 1). Anthropometric data (age, weight, height and BMI) were collected for each participant and there were no statistical differences in baseline parameters (see Table 1) or baseline biochemistry (Additional file 1) between the two groups.

Bottom Line: There were no reported adverse effects (i.e. changes to health and well-being) or serum biochemical changes with MMST versus placebo.Our data indicate that oral MMST is safe, is absorbed and undergoes sufficient metabolism in vivo to raise fasting serum silicon levels, consistent with other well absorbed forms of dietary silicon (e.g. orthosilicic acid).It thus appears to be a suitable silicon supplement.

View Article: PubMed Central - HTML - PubMed

Affiliation: MRC Human Nutrition Research, Elsie Widdowson Laboratory, Fulbourn Road, Cambridge, CB1 9NL, UK. ravin.jugdaohsingh@mrc-hnr.cam.ac.uk.

ABSTRACT

Background: Monomethylsilanetriol (MMST) has been used for decades as an oral silicon supplement for bone and connective tissue health, although there are no formal data on its in vivo utilisation or safety following sustained dosing.

Methods: To investigate whether MMST contributes to the body pool of silicon and, secondly, to establish its safety following 4 weeks' supplementation in humans, twenty-two healthy pre-menopausal women (22-38 years) were recruited and supplemented with MMST at the maximum daily recommended dose (10.5 mg Si/day) for 4 weeks in a double-blind, randomised, placebo-controlled, cross-over design (i.e. 8 weeks in total). Fasting serum and urine samples were collected at baseline and at the end of the 4-week supplementation/placebo periods for analysis of total silicon by inductively coupled plasma optical emission spectrometry, MMST by proton nuclear magnetic resonance spectroscopy and full serum biochemistry. Participants also reported on, by questionnaire, their health, well-being and quality of life at 0, 4 and 8 weeks.

Results: Overall, 4-weeks supplementation with MMST significantly increased total fasting Si concentrations in serum and urine (P ≤ 0.003; paired t-test). MMST was semi-quantifiable in serum and quantifiable in urine, but only accounted for ca. 50% and 10%, respectively, of the increased total-Si concentration. There were no reported adverse effects (i.e. changes to health and well-being) or serum biochemical changes with MMST versus placebo.

Conclusions: Our data indicate that oral MMST is safe, is absorbed and undergoes sufficient metabolism in vivo to raise fasting serum silicon levels, consistent with other well absorbed forms of dietary silicon (e.g. orthosilicic acid). It thus appears to be a suitable silicon supplement.

No MeSH data available.


Related in: MedlinePlus